Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone and Telmisartan in Metabolic Syndrome
NCT00926341Phase 4
Key facts
- Status
- Completed
- Start
- Oct 2006
- Primary completion
- Jun 2008
- Countries
- 1
- Sponsor
- Aligarh Muslim University
- Modality
- Small Molecules
- Conditions
- metabolic syndrome
01
Overview
Phase 4, randomised, open-label trial of pioglitazone and telmisartan in metabolic syndrome, sponsored by Aligarh Muslim University. Started Oct 2006; status: completed.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Patients aged 30-70 with metabolic syndrome (NCEP-ATP III criteria) excluding those with significant renal/hepatic/heart failure or recent use of ACE inhibitors, ARBs, or TZDs.
04
Registry description
Metabolic syndrome, labeled as the world's latest epidemic, is the force behind the global epidemic of Type 2 Diabetes Mellitus and Cardio Vascular Diseases. This emerging epidemic is an important public health problem for South Asians in their homeland and worldwide.
Pharmacological therapy is a critical step in the management of patients with metabolic syndrome. In general, treatment for metabolic syndrome, that targets all or most of the components of metabolic syndrome is either deficient or non-existent. The study presented here is the pioneering work in the management of metabolic…
Beyond the preview
Go deeper on NCT00926341.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00926341.